New antiviral agents for the treatment of hepatitis C: ABT-450

CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages

(2013) Fasiha Kanwal et al.   GASTROENTEROLOGY

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

(2013) Eric Lawitz et al.   JOURNAL OF HEPATOLOGY

ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection

(2013) Tarik Asselah   JOURNAL OF HEPATOLOGY

3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

(2013) K.V. Kowdley et al.   JOURNAL OF HEPATOLOGY

Novel therapies for hepatitis C — one pill fits all?

(2013) Michael P. Manns et al.   NATURE REVIEWS DRUG DISCOVERY

Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

(2013) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

(2013) Qing-Lei Zeng   WORLD JOURNAL OF GASTROENTEROLOGY

Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor

(2012) Samuel James Matthews et al.   CLINICAL THERAPEUTICS

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

(2011) Varun Garg et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin

(2009) Michelle Martinot-Peignoux et al.   HEPATOLOGY

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4

(2008) Shu-Feng Zhou   CURRENT DRUG METABOLISM